BioCardia outlined a regulatory path for its CardiAMP autologous cell therapy, targeting a Shonin pre-market submission to Japan's PMDA in Q4 2026 with potential market clearance by Q4 2027. The confirmatory CardiAMP HF II trial is enrolling at four U.S. centers under an FDA pathway that may support a Pre-Marketing Application, while a separate De Novo submission seeks independent clearance for the Helix transendocardial delivery catheter.
Key Points
- Shonin submission to Japan's PMDA planned for Q4 2026
- Confirmatory CardiAMP HF II trial enrolling at four U.S. centers
- Helix catheter pursues independent FDA clearance as delivery platform
Longevity Analysis
Heart failure represents a failure of the heart's capacity to repair itself after ischemic injury, and cell-based approaches aim to restore contractile tissue rather than manage symptoms downstream. Separating the delivery catheter from the therapy it carries creates infrastructure that any cell, gene or protein candidate targeting cardiac tissue could use — a platform decision with implications well beyond this single program. Regulatory sequencing across two jurisdictions determines how quickly regenerative cardiac interventions reach the patients whose circulatory reserve is already declining.
Original published by Longevity.Technology.